Jacob J Adashek
Overview
Explore the profile of Jacob J Adashek including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
82
Citations
1002
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Adashek J, Nikanjam M, Kurzrock R
Nat Rev Drug Discov
. 2025 Mar;
PMID: 40050521
Protein kinases are crucial targets for cancer treatment as they orchestrate important signals for oncogenesis and are often aberrantly activated owing to genomic alterations. In the past two decades, multiple...
2.
Hsieh M, Nishizaki D, Adashek J, Kato S, Kurzrock R
Biomark Res
. 2025 Feb;
13(1):32.
PMID: 39988665
The discovery of Toll-like receptors (TLRs) and their role in dendritic cells earned the Nobel Prize for 2011 because TLRs profoundly enhanced our understanding of the immune system. Specifically, TLR3...
3.
Liu J, Farrow M, Seymour L, Desai J, Loong H, Ivy P, et al.
J Clin Oncol
. 2025 Jan;
43(6):735-747.
PMID: 39808749
Purpose: Over the past 15 years, the landscape of early phase clinical trials (EPCTs) has undergone a remarkable expansion in both quantity and intricacy. The proliferation of sites, trials, sponsors,...
4.
If it is a solid tumor target, then it may be a hematologic cancer target: Bridging the great divide
Adashek J, Munoz J, Kurzrock R
Med
. 2024 Dec;
6(1):100550.
PMID: 39689708
Tumor-agnostic US Food and Drug Administration approvals are transforming oncology. They include larotrectinib/entrectinib/repotrectinib (NTRK fusions), selpercatinib (RET fusions), dabrafenib/trametinib (BRAF mutations), pembrolizumab/dostarlimab (microsatellite instability), pembrolizumab (high tumor mutational burden), and...
5.
Adashek J, Brodsky M, Levis M
NPJ Precis Oncol
. 2024 Sep;
8(1):197.
PMID: 39256524
The cytogenetic abnormality inv(2)(p23q13) in acute myeloid leukemia (AML) results in a fusion of RANBP2 with ALK. This fusion makes ALK constitutively active and acts as a driver for the...
6.
Nikanjam M, Wells K, Kato S, Adashek J, Block S, Kurzrock R
Med
. 2024 May;
5(7):689-717.
PMID: 38749442
Growth and immune process dysregulation can result in both cancer and nonmalignant disease (hereditary or acquired, with and without predisposition to malignancy). Moreover, perhaps unexpectedly, many nonmalignant illnesses harbor genomic...
7.
8.
Adashek J, Kato S, Sicklick J, Lippman S, Kurzrock R
Cancer Treat Rev
. 2024 Mar;
125:102721.
PMID: 38522181
Cancer is traditionally diagnosed and treated on the basis of its organ of origin (e.g., lung or colon cancer). However, organ-of-origin diagnostics does not reveal the underlying oncogenic drivers. Fortunately,...
9.
Adashek J, Pandya C, Maragakis N, De P, Cohen P, Kato S, et al.
BMC Med
. 2024 Feb;
22(1):74.
PMID: 38369520
Background: Neuregulin-1 (NRG1) is implicated in both cancer and neurologic diseases such as amyotrophic lateral sclerosis (ALS); however, to date, there has been little cross-field discussion between neurology and oncology...
10.
Adashek J, Kato S, Nishizaki D, Pabla S, Nesline M, Previs R, et al.
Am J Cancer Res
. 2024 Feb;
14(1):368-377.
PMID: 38323282
Immune checkpoint inhibitors have revolutionized the treatment landscape for patients with cancer. Multi-omics, including next-generation DNA and RNA sequencing, have enabled the identification of exploitable targets and the evaluation of...